Compare iShares Self-Driving EV and Tech (IDRV) vs TG Therapeutics Inc (TGTX) Price & Performance

IDRV trades at $37.24, down 0.35% on the day, with a bullish technical signal driven by moving averages. The stock is positioned near its pivot point of $37, with key resistance at $38 and support at $36. Recent news highlights strong global EV sales growth and China's ambitious 2030 fleet target, supporting the thematic focus of the fund.

The outlook for IDRV is supported by positive industry trends in electric vehicles, though the absence of key valuation and profitability ratios limits fundamental assessment. Risks include competitive pressures and regulatory changes, while analyst sentiment is mixed with a slight bullish bias. The stock's performance remains tied to broader EV market dynamics.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.